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2-Chlorohexadecanal (2-ClHDA), a chlorinated fatty aldehyde, is formed via attack on ether-
phospholipids by hypochlorous acid (HOCl) that is generated by the myeloperoxidase–hydrogen
peroxide–chloride system of activated leukocytes. 2-ClHDA levels are elevated in atherosclerotic lesions,
myocardial infarction, and neuroinﬂammation. Neuroinﬂammatory conditions are accompanied by
accumulation of neutrophils (an ample source of myeloperoxidase) in the brain. Microvessel damage by
inﬂammatory mediators and/or reactive oxidants can induce blood–brain barrier (BBB) dysfunction, a
pathological condition leading to cerebral edema, brain hemorrhage, and neuronal death. In this in vitro
study we investigated the impact of 2-ClHDA on brain microvascular endothelial cells (BMVEC), which
constitute the morphological basis of the BBB. We show that exogenously added 2-ClHDA is subject to
rapid uptake and metabolism by BMVEC. Using C16 structural analogues of 2-ClHDA we found that the
cytotoxic potential decreases in the following order: 2-ClHDA4hexadecanal4palmitic acid4
2-ClHDA-dimethylacetal. 2-ClHDA induces loss of barrier function, mitochondrial dysfunction, apoptosis
via activation of caspase 3, and altered intracellular redox balance. Finally we investigated potential
protective effects of several natural polyphenols on in vitro BBB function. Of the compounds tested,
phloretin almost completely abrogated 2-ClHDA-induced BMVEC barrier dysfunction and cell death.
These data suggest that 2-ClHDA has the potential to induce BBB breakdown under inﬂammatory
conditions and that phloretin confers protection in this experimental setting.
& 2012 Elsevier Inc.Open access under CC BY-NC-ND license.Most regions of the brain operate within a well-controlled
environment separated from the peripheral circulation by the
neurovascular unit [1]. There, brain microvascular endothelial
cells (BMVEC) form the physical basis of the blood–brain barrier
(BBB) by the formation of tight and adherens junction com-
plexes [2]. These complexes prevent paracellular transport of
molecules and cells, thereby maintaining brain homeostasis
via elaborately regulated transport mechanisms [1,3]. However,
inﬂammatory processes, including endothelial transmigration of
leukocytes and activation of glial cells and subsequent production
of inﬂammatory mediators and/or reactive oxygen species (ROS),
can induce BBB permeability and amplify neurodegeneration [4].
Dysfunctional mitochondria, amyloid-b peptides, redox-active
iron, and the NADPH-oxidase complex are potential sources of
reactive species at the neurovasculature and in deeper brain
regions [5,6].5
W. Sattler).
Y-NC-ND license.Short- and long-term alterations in brain lipid composition as a
consequence of neuroinﬂammation and/or oxidative stress are
casually involved in central nervous system-related disorders and
injury [5]. Within the cerebral lipid subclasses ether-phospholipids
(predominantly plasmalogens) take a central structural and func-
tional role in brain function [7]. Plasmalogen deﬁciency results in
severe and long-lasting developmental alterations of the cerebellum
[8], and decreased plasmalogen content is linked to neurodegenera-
tive diseases [9,10].
During activation of phagocytes the myeloperoxidase (MPO)–
H2O2–chloride system contributes to oxidant generation [11,12].
Increasing evidence points toward MPO as a disease-amplifying
enzyme in neurodegeneration [6]. In multiple sclerosis, MPO is
present in microglia/macrophages at lesion sites [13,14]. Cortical
demyelination is associated with increased MPO activity [15,16]
and neuroinﬂammation increases cerebral MPO levels [17].
2-Chlorohexadecanal (2-ClHDA) is a naturally occurring chlori-
nated fatty aldehyde generated by HOCl-targeting of the vinyl-
ether bond of plasmalogens. 2-ClHDA is generated by activated
neutrophils [18,19] and monocytes [20] and concentrations are
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fused myocardium [22], and inﬂamed brain tissue [17]. 2-ClHDA is
a potent neutrophil chemoattractant [19] and a potent inhibitor of
vasculoprotective endothelial nitric oxide synthase (eNOS) [18].
Neutrophils immobilize and kill invading microbes extracellu-
larly through the formation of neutrophil extracellular traps
(NETs) [23]. During this process, termed NETosis, neutrophil
MPO synergizes with elastase in promoting chromatin deconden-
sation and NET formation [24]. Neutrophils are able to produce
and secrete chlorinated lipids [25]. Thus it is possible that the
MPO–H2O2–chloride system leads to modiﬁcation and/or chlor-
ination of the endogenous neutrophil plasmalogen pool that could
amplify modiﬁcation of extracellular targets at the BBB.
Oxidative stress contributes to BBB dysfunction in neurode-
generative diseases. One potential contributor in this setting
is neutrophil- or glia-derived MPO that is capable of oxidati-
vely targeting plasmalogens [19,20], thereby generating chlori-
nated lipids including 2-ClHDA. This study aimed to elucidate
the impact of exogenously added 2-ClHDA on BMVEC metabolic
activity and function (mitochondrial and endothelial barrier
function). To pursue potential pharmacotherapeutic applications,
naturally occurring polyphenols were tested for their potential to
ameliorate lipotoxic effects displayed by 2-ClHDA.Materials and methods
Materials
Cell culture supplies were from Gibco (Vienna, Austria), PAA
Laboratories (Linz, Austria), Costar (Vienna, Austria), or VWR
(Austria). Dulbecco’s modiﬁed Eagle’s medium (DMEM) Ham’s
F12 and hydrocortisone were from Sigma–Aldrich (Vienna,
Austria). Electrical cell-substrate impedance sensing (ECIS)
electrode arrays (8W10Eþ) were from Ibidi (Martinsried,
Germany). Dimethyl sulfoxide (DMSO), sodium hypochlorite
(NaOCl), 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium
bromide (MTT), palmitic acid, colchicine, apigenin, curcumin,
genistein, naringenin, phloretin, phloridzin, resveratrol, N,N-
diisopropylethylamine, pentadecanoic acid, pentadecanol,
heptadecanoic acid, dipalmitoylphosphatidylcholine, glycerol
tripalmitate, cholesteryl palmitate, N-acetylcysteine (NAC), pen-
taﬂuorobenzyl (PFB) hydroxylamine, PFB bromide, and penta-
ﬂuorobenzoyl (PFBoyl) were from Sigma–Aldrich. Silica gel
60 plates were from Merck (Darmstadt, Germany). Staurosporine
was from Calbiochem (La Jolla, CA, USA). 5-(And-6)-carboxy-
20,70-dichlorodihydroﬂuorescein diacetate (carboxy-H2DCFDA)
and 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimidazolylcarbocya-
nine iodide (JC-1) were from Molecular Probes (Invitrogen, Vienna,
Austria). Phenylmethylsulfonyl ﬂuoride (PMSF), aprotinin, leupeptin,
and pepstatin were from Sigma–Aldrich. Polyvinylidene diﬂuoride
(PVDF) transfer membrane (Biotrace PVDF) was from Pall Corp.
(Vienna, Austria). Detergents and other chemicals were from Sigma–
Aldrich. ECL SuperSignal Western blotting substrate was obtained
from Pierce (Rockford, IL, USA) and CURIX Ultra UV-G X-ray ﬁlms
were from Agfa (Mortsel, Belgium). Polyclonal rabbit anti-human
caspase 3 antibody was from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) and horseradish peroxidase-conjugated goat anti-rabbit
IgG was from Pierce. All other chemicals and solvents were from
Sigma–Aldrich or Roth (Vienna, Austria).
Isolation and culture of primary porcine brain microvascular
endothelial cells
BMVEC were isolated from porcine brains obtained from
the local slaughterhouse by a combination of mechanicaldisintegration, enzymatic digestion, and centrifugation steps [26].
After removal of meninges and the secretory areas, the brain cortex
(gray and white matters) was minced using a sterile cutter with
staggered rolling blades. Minced tissue was suspended in ‘‘pre-
paration medium’’ (M199 supplemented with penicillin/strepto-
mycin (P/S; 100 mg/ml), gentamycin (100 mg/ml), and glutamine
(0.68 mM)) and incubated with solid dispase (0.1%, w/v) for 1 to
2 h at 37 1C in a water bath with gentle stirring. Dextran solution
(16%, w/v) was added to get a ﬁnal 10% (w/v) dextran suspension
followed by centrifugation at 6800 g for 10 min at 4 1C. The
resulting pellet was resuspended in ‘‘medium A’’ (M199 supple-
mented with P/S (100 mg/ml), gentamycin (100 mg/ml), and gluta-
mine (0.68 mM, and 10% ox serum)). Larger vessels were separated
by a ﬁltration step through a 180-mm nylon mesh. Microvessels
were digested with 0.03% (w/v) collagenase/dispase for 5 min at
37 1C in a water bath with gentle stirring. After collection of
released BMVEC aggregates by low-spin centrifugation at 140 g
for 10 min at room temperature (RT) they were further puriﬁed by
density gradient centrifugation. Cells obtained from one brain were
resuspended in 5 ml medium A and centrifuged on a discontinuous
Percoll gradient (20 ml 1.03 g/ml bottom-layered with 15 ml
1.07 g/ml) at 1300 g for 10 min at RT in a swinging bucket rotor
without brake. BMVEC clusters, which were gathered at the inter-
face of the two phases, were washed in medium A and plated onto
six to eight 75 cm2 collagen-coated culture ﬂasks. After 1 day in
culture the cells were washed twice with phosphate-buffered
saline (PBS) and cultivated in ‘‘medium B’’ (medium A without
gentamycin).
After 2 to 3 days, when conﬂuence was almost reached, BMVEC
were subcultured by trypsinization and seeded onto collagen-
coated cell culture ware (6-, 12-, 24-, and 96-well plates, 60 mg/ml
collagen in PBS) or onto ECIS arrays (200 mg/ml collagen in
150 mM NaCl) at densities between 20,000 (multiwell plates)
and 40,000 cells/cm2 (ECIS arrays).
Determination of NaOCl concentration
The concentration of NaOCl (termed reagent HOCl) was deter-
mined for each experiment using the molar absorption coefﬁcient
for NaOCl of 350 cm1 at 292 nm at pH 12. Dilutions of NaOCl
were prepared in Milli-Q water.
Cell experiments
Before starting cell culture experiments BMVEC were preincu-
bated overnight with serum-free medium B. For ECIS experiments
medium B was replaced by ‘‘induction medium’’ (DMEM Ham’s
F12 medium supplemented with P/S (100 mg/ml), glutamine
(0.68 mM), and hydrocortisone (500 nM; to induce formation of
tight junctions)). During cell experiments BMVEC were incubated
in serum-free medium B or induction medium in the absence or
presence of 2-ClHDA, reagent HOCl, structural analogues
of 2-ClHDA (palmitic acid, hexadecanal (HDA), and 2-ClHDA-
dimethylacetal (dma)), polyphenols, or inducers of apoptosis
(staurosporine and colchicine; 1 mM each) for the indicated time
periods. Freshly deprotected 2-ClHDA and HDA as well as other
structural analogues of 2-ClHDA, polyphenols, and staurosporine
were prepared as stock solutions in DMSO. For each cell experi-
ment using 2-ClHDA (or structural analogues) the ﬁnal concen-
tration of DMSO in the medium was 0.4% (v/v). Reagent HOCl and
colchicine were prepared as 250 stock solutions in water.
Electrical cell-substrate impedance sensing
To determine the effects of 2-ClHDA and phloretin on barrier
function, impedance measurement was performed using an ECIS
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on collagen-coated gold electrodes of 8W10Eþ arrays and impe-
dance was recorded in real time at 1-min intervals at 4 and
64 kHz. After induction of tight junctions by hydrocortisone the
average baseline impedance readings varied between 2000 and
5000 O at 4 kHz and between 600 and 800 O at 64 kHz. Experi-
ments were started when a stable basal impedance of 42000 O
at 4 kHz was obtained.
MTT test
To investigate the effects of 2-ClHDA, structural analogues of
2-ClHDA, and reagent HOCl on BMVEC metabolic activity in the
absence or presence of polyphenols the MTT test was used [27].
BMVEC were grown in 12-, 24-, or 96-well plates to conﬂuence
and treated with 2-ClHDA or reagent HOCl in serum-free medium
B at the indicated concentrations and for the indicated time
periods. In the case of cotreatment, cells were preincubated with
polyphenols at the indicated concentrations for 30 min before
addition of 2-ClHDA. After treatment, the medium was replaced
by serum-free medium (100–500 ml per well) containing MTT
(1.2 mM) and the cells were incubated for 1 h under standard
conditions. The cells were washed (PBS) and lysed (isopropanol/
1 M HCl, 25/1 (v/v); 100 ml) on a rotary shaker (1000 rpm,
15 min). Absorbance was measured at 570 nm on a Victor 1420
multilabel counter (Wallac) and corrected for background absorp-
tion (650 nm).
JC-1 assay
To examine the mitochondrial membrane potential (Dcm) of
BMVEC after treatment with 2-ClHDA or reagent HOCl, the JC-1
assay was performed [28]. Cells were grown to conﬂuence in
black 96-well plates (Greiner, Linz, Austria) before 2-ClHDA or
reagent HOCl was added in serum-deprived medium at the
indicated concentrations and for the indicated time periods. Cells
were then incubated with JC-1 (10 mM, added to serum-free
medium B as 2 mM stock solution in DMSO, 100 ml per well) at
37 1C in the dark for 90 min followed by two washing steps with
PBS. Fifty microliters of PBS was then added to each well and
ﬂuorescence intensities were read at 485/535 nm (excitation/
emission) for detection of the green substrate and 544/590 nm
(excitation/emission) for detection of the red substrate using a
Victor 1420 multilabel counter.
Measurement of carboxy-H2DCFDA oxidation
After internalization and subsequent hydrolysis the redox indi-
cator probe carboxy-H2DCFDA is converted to carboxy-H2DCF,
which, in the presence of oxidant species, undergoes oxidation to
the ﬂuorescent carboxy-DCF [29]. BMVEC were grown to conﬂuence
in six-well plates before the cells were incubated with H2DCFDA
dissolved in PBS (10–25 mM, added as 300 stock solution in
DMSO) for 1 h at 37 1C in the dark. Subsequently, PBS was replaced
by serum-free medium B containing the indicated concentrations of
2-ClHDA and the cells were incubated at 37 1C in the dark. Incuba-
tions were stopped by washing the cells two times with ice-cold PBS
and, then, the plates were kept on ice for 10 min. Cell lysis was
performed with 300 ml lysis solution (3% Triton X-100 in PBS) on a
rotary shaker (1350 rpm) at 4 1C in the dark for 60 min. Afterward,
50 ml EtOH was added to each well and shaking was continued for
another 15 min to ensure complete solubilization of deacetylated
and oxidized DCF. The cell lysates were transferred to Eppendorf
tubes and centrifuged to remove cellular debris (13,000 rpm, 4 1C,
10 min). Two hundred microliters of the supernatant were trans-
ferred to black 96-well microtiter plates and ﬂuorescence intensitywasmeasured at 485/535 nm (excitation/emission) on a Victor 1420
multilabel counter. An aliquot of the supernatant was used to
determine the protein concentration using the BCA assay. To
investigate whether DCF ﬂuorescence is sensitive toward altered
intracellular thiol content, BMVEC were incubated in the presence of
NAC (5 mM, 1 h) followed by the addition of 2-ClHDA (25 mM, 3 h).
Analysis of (pro)caspase 3 activation
Western blotting
BMVEC were plated in six-well trays and allowed to grow to
conﬂuence. Cells were incubated in the absence or presence of
2-ClHDA, reagent HOCl, colchicine, or staurosporine at the indi-
cated concentrations and for the indicated time periods. For
protein isolation, the cells were washed twice with ice-cold PBS
and then scraped in 50 ml lysis buffer containing PMSF and 1 mg/ml
each aprotinin, leupeptin, and pepstatin. After the cellular debris
was removed by centrifugation (13,000 rpm, 4 1C, 10 min) the
protein content was determined using the Bradford assay (Bio-
Rad). Protein extracts were diluted in sample buffer and heated to
95 1C for 5 min before the proteins were separated by SDS–PAGE
(10 or 12% polyacrylamide gels, 150 V). Subsequently, the proteins
were electrophoretically transferred to PVDF membranes (150 mA,
45 min). Nonspeciﬁc adsorption was blocked by incubation with
5% (w/v) low-fat milk powder in Tris-buffered saline/Tween 20
(TBS-T). Rabbit anti-caspase 3 antibody (diluted 1:400 in 5%
low-fat milk in TBS-T) was applied by overnight incubation at
4 1C. Immunoreactive bands were visualized using horseradish
peroxidase-conjugated goat anti-rabbit IgG (1:5000 in 5% (w/v)
nonfat milk powder in TBS-T, 2 h, RT) and subsequent ECL Super-
Signal development.
Caspase 3 activity
BMVEC were cultured to conﬂuence in 24-well plates. Subse-
quently, the cells were incubated with 2-ClHDA, staurosporine,
and/or phloretin in serum-deprived medium at the indicated
concentrations for 5 h. Cellular caspase 3 activity was determined
using the EnzChek Caspase 3 Assay Kit 2 (Molecular Probes)
according to the manufacturer’s instructions. The assay is based
on rhodamine-derived substrate Z-DEVD-R110, which yields a
ﬂuorescent product upon proteolytic cleavage by active caspase 3.
To conﬁrm that the observed ﬂuorescence signal in induced cells
was due to the activity of caspase 3-like proteases the inhibitor
Ac-DEVD-CHO was added to cell lysates. Fluorescence intensities
were measured at 484/540 nm (excitation/emission) in black
96-well microtiter plates on a Victor 1420 multilabel counter.
Determination of cellular ATP levels
ATP levels of BMVEC were measured using the ATP Determi-
nation Kit according to the manufacturer’s (Molecular Probes)
recommendations. Brieﬂy, BMVEC were cultured to conﬂuence in
96-well plates before 2-ClHDA and/or polyphenols were added in
serum-deprived medium at the indicated concentrations. After
5 h the cells were washed twice with PBS and boiled for 5 min in
100 ml of distilled water. Ten microliters of each sample or 10 ml
of each dilution for the ATP standard curve (0–5000 nM) were
transferred to a well of a 96-well plate before 90 ml of reaction
solution was added and mixed. Finally, after a 10-s delay the
chemiluminescence was measured on a VICTOR3 multilabel
reader (Wallac).
2-ClHDA decay in the cellular supernatant
BMVEC were plated in six-well trays and allowed to grow to
conﬂuence. Cells were incubated with 4.1 mg 2-ClHDA (250
Table 1
Identiﬁcation and quantiﬁcation of analytes by SIM.
Analyte (PFB
derivative)
m/z Internal standard
(PFB-derivative)
m/z Internal
standard
(ng)
2-ClHDA 288/290, 414 2-Cl[13C8]HDA 288/290,
422
100
2-ClHA 289/291, 254 Pentadecanoic acid
Heptadecanoic acid
241
269
100
2-ClHOH 470/472, 435 Pentadecanol 422 100
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indicated times lipids from 1 ml of culture medium were
extracted twice in 2 ml hexane/methanol (5/1; v/v) in the pre-
sence of 100 ng 2-Cl[13C8]HDA as internal standard, which was
synthesized as described previously [17]. After conversion to the
corresponding PFB-oxime derivatives 2-ClHDA was quantitated
by negative-ion chemical ionization gas chromatography mass
spectrometry (NICI–GC–MS, see below). A one-phase exponential
decay model (Ct ¼ C0 ekt) was used to ﬁt experimental data
using Prism 5.0 (GraphPad Software).
Uptake and metabolism of 2-ClHDA by BMVEC
BMVEC plated in six-well trays were grown to conﬂuence.
Cells were incubated with 4.1 mg 2-ClHDA for the indicated time
periods. Subsequently, lipids from 1 ml of culture medium were
extracted twice in 2 ml hexane/methanol (5/1; v/v) in the pre-
sence of 2-Cl[13C8]HDA, pentadecanoic acid, and pentadecanol
(each 100 ng). Cellular lipids were extracted in the presence of
internal standards (100 ng each) using two consecutive extrac-
tions (30 min at RT) with 1 ml of hexane/isopropanol (3/2; v/v) on
a rotary shaker (1000 rpm). After preparation of PFB-oxime and
PFB-ester derivatives, 2-ClHDA, 2-chlorohexadecanoic acid (2-
ClHA), and 2-chlorohexadecanol (2-ClHOH) were quantitated by
NICI–GC–MS.
2-ClHA distribution in complex lipids
BMVEC plated in petri dishes (10 cm) were grown to conﬂu-
ence (5.5106 cells). Cells were incubated with 17.8 mg 2-ClHDA
(250 stock in DMSO; 8 mM, ﬁnal concentration) for the indicated
time periods. Subsequently, cellular lipids were extracted using
two consecutive extractions (30 min at RT) with 5 ml of hexane/
isopropanol (3/2, v/v) on a rotary shaker (1000 rpm). For isolation
of complex lipid fractions cellular lipids were separated on silica
gel 60 plates using hexane/diethyl ether/acidic acid (70/30/1, v/v/v)
as the mobile phase. Fractions comigrating with dipalmitoylpho-
sphatidylcholine, tripalmitate, and cholesteryl palmitate were
scraped off, supplemented with 100 ng heptadecanoic acid as
internal standard, and extracted from the TLC sorbent using
CHCl3/MeOH (2/1, v/v). For generation of free fatty acids, lipid
extracts were dispersed in 500 ml 0.5 M NaOH by sonication and
vortexing and incubated for 1 h in a boiling water bath. Subse-
quently, the samples were cooled to RT, neutralized by addition of
500 ml 0.5 M HCl, and acidiﬁed with acetic acid. The released
free fatty acids were extracted, converted to the corresponding
PFB-esters, and analyzed by NICI–GC–MS.
Derivatization procedures
Preparation of PFB-oxime derivatives of 2-ClHDA was per-
formed as previously described [17]. Fatty acids were converted
to the corresponding PFB-ester derivatives in 100 ml 0.35% (v/v)
PFB-bromide in acetonitrile and 20 ml N,N-diisopropylethylamine
for 30 min at RT. Fatty alcohols were converted to PFB-esters
using 100 ml 0.4% (v/v) PFBoyl chloride in acetonitrile for 1 h at
80 1C. Derivatization reagents were evaporated on an Eppendorf
concentrator. Samples were redissolved in 100 ml hexane, trans-
ferred to autosampler vials, and stored at 20 1C until GC–MS
analysis.
NICI–GC–MS analysis
Samples were separated on a Thermo Scientiﬁc Trace GC Ultra
(helium was used as carrier gas, 2 ml/min) with an SGE BPX5
capillary column (15 m, 0.25 mm inner diameter, 0.25 mm methylsilicone ﬁlm coating) and analyzed using a DSQII mass spectro-
meter (Thermo Scientiﬁc). Injector temperature was set to 230 1C
and ion source temperature was 180 1C. The oven temperature
was maintained at 100 1C for 5 min, increased during the ﬁrst
ramping step at a rate of 20 1C/min to 175 1C, and held at 175 1C
for 1 min. In the second ramping step the temperature was raised
at a rate of 15 1C/min to 280 1C and held at 280 1C for an additional
2 min. All spectra were monitored in NICI (methane was used as
reagent gas), either in full scan or using selected ion monitoring
mode (SIM). In SIM, target compounds were identiﬁed at
molecule-speciﬁc mass-to-charge ratios (Table 1) and the char-
acteristic isotope distribution of chlorine (Cl35/Cl37, 3/1). Quantita-
tion was performed by peak area comparison with internal
standards (Table 1).
Statistical analyses
Data are presented as means 7 SD. To test differences in
groups, statistical signiﬁcance was determined by Student’s t test
or one- or two-way ANOVA with Bonferroni correction (using the
GraphPad 5.0 Prism package) as indicated. All values of p r 0.05
were considered signiﬁcant.Results
Uptake and metabolism of 2-ClHDA by BMVEC
To test whether 2-ClHDA is taken up by BMVEC, cells were
incubated with the aldehyde (15 nmol/well). Cellular and med-
ium lipids were extracted and quantitatively analyzed as PFB-
oximes by NICI–GC–MS. 2-ClHDA concentrations in the cellular
supernatant were ﬁtted to an exponential decay revealing a half-
life of 120 min (Fig. 1A). The decay of 2-ClHDA in the medium
was accompanied by a concomitant increase in cellular 2-ClHDA
concentrations reaching a maximum of 1 nmol (Fig. 1B; corre-
sponding to approx 7% of 2-ClHDA initially present in the
medium) after 120 min.
To get an indication of how 2-ClHDA is metabolized by BMVEC
the formation of the redox metabolites [30] 2-ClHOH and 2-ClHA
was analyzed by NICI–GC–MS (Figs. 2A and B). Within the ﬁrst
2 h 2-ClHOH and 2-ClHA accumulated in the cell monolayer at
concentrations of 1.9 and 0.4 nmol. Whereas 2-ClHOH concentra-
tions were slightly decreasing at longer time periods, 2-ClHA
levels remained constant. Both chlorinated lipids were detectable
in the culture medium (approx. 10% of cell-associated 2-ClHOH
and 30% of cell-associated 2-ClHA), indicating cellular release of
metabolites and/or synthesis via extracellular redox events.
A time course of the precursor (2-ClHDA added at t¼0)–
product relationship (sum of 2-ClHDA, 2-ClHOH, and 2-ClHA in
cells and medium, termed 2-ClHX) is shown in Fig. 2C. It is
evident that at early time points (up to 60 min) the loss of
2-ClHDA and accumulation of 2-ClHX are equal. Nevertheless
Fig. 1. Uptake kinetics of exogenous 2-ClHDA by BMVEC. Cells (9105) were incubated with 2-ClHDA (stock added in DMSO; ﬁnal aldehyde concentration 10 mM). At the
indicated times, cellular lipids and lipids of the culture medium were extracted in the presence of 100 ng 2-Cl[13C8]HDA. After conversion to the corresponding PFB-oxime
derivatives the 2-ClHDA content of (A) the culture medium and (B) BMVEC was quantitated by NICI–GC–MS analysis. Results represent mean values7SD of three
independent experiments. Experimental data of 2-ClHDA decay in the culture medium (A) were ﬁtted by nonlinear regression analysis (R2¼0.98).
Fig. 2. Metabolism of exogenous 2-ClHDA by BMVEC. Cells (9105) were incubated with 2-ClHDA (stock added in DMSO; ﬁnal concentration 10 mM). At the indicated
times, cellular lipids and lipids of the culture medium were extracted in the presence of pentadecanol and pentadecanoic acid as internal standards. After conversion to
PFB-ester derivatives, 2-chlorohexadecanoic acid (2-ClHA) and 2-chlorohexadecanol (2-ClHOH) concentrations were quantitated from (A) cellular and (B) medium lipid
extracts by NICI–GC–MS analysis. (C) Loss of 2-ClHDA vs recovery of 2-ClHX (the sum of 2-ClHDA, 2-ClHOH, and 2-ClHA in cells and medium). (D) Cells (5.5106) were
incubated with 2-ClHDA (stock added in DMSO; ﬁnal aldehyde concentration 8 mM). At the indicated times, cellular lipids were extracted. After preseparation of lipid
classes by TLC and subsequent extraction from TLC plates, free fatty acids were generated by alkaline hydrolysis. After conversion to the corresponding PFB-ester
derivatives, 2-ClHA concentrations were quantitated by NICI–GC–MS with heptadecanoic acid as internal standard. Results represent mean values7SD of triplicate
determinations. PL, phospholipid; TG, triglyceride; CE, cholesteryl ester.
A. U¨llen et al. / Free Radical Biology and Medicine 53 (2012) 1770–17811774recovery of 2-ClHDA and its metabolites after 5 h accounts for
only 25% of total added 2-ClHDA.
One of the pathways contributing to loss of 2-ClHDA is its
oxidation to 2-ClHA and subsequent reincorporation into thestorage pool of complex lipids [30]. To clarify the ability of BMVEC
to form chlorinated complex lipids, cells were incubated in the
presence of 2-ClHDA and cellular lipids were preseparated by TLC.
Bands comigrating with phospholipids, triglycerides, and cholesteryl
A. U¨llen et al. / Free Radical Biology and Medicine 53 (2012) 1770–1781 1775esters were scraped, hydrolyzed, and analyzed by NICI–GC–MS.
These experiments revealed that after 6 h approximately 63, 24, and
13% of 2-ClHA was present in the phospholipid, triglyceride, and
cholesteryl ester fractions. This percentage distribution remained
grossly unchanged after 12 h (Fig. 2D).2-ClHDA severely impairs metabolic activity of BMVEC
2-ClHDA signiﬁcantly impaired cellular MTT reduction in a time-
and concentration-dependent manner (Fig. 3A) at much lower
concentrations compared to reagent HOCl (Fig. 3B). Of note, LC50
concentrations of reagent HOCl were approximately 10- to 20-fold
higher than for 2-ClHDA. DMSO used as vehicle for 2-ClHDA delivery
was without effects on MTT reduction (Supplementary Fig. IA).Fig. 3. 2-ClHDA impairs metabolic activity of BMVEC. Cells were incubated in the absence
indicated time periods. Metabolic activity was analyzed by the MTT test. Results are expres
(B) determinations.
Fig. 4. Cytotoxic potential depends on functional groups. (A) Structures of the four diffe
the compounds shown in (A). After treatment, BMVEC metabolic activity was analyz
values7SD of triplicate determinations (ns, not signiﬁcant; np o 0.05, nnp o 0.01, nnnCytotoxic properties have structural speciﬁcity
2-ClHDA contains two functional groups attached to an alipha-
tic chain. To get an indication of the structural requirements that
mediate cytotoxicity, three structurally related C16 analogues
(Fig. 4A), namely HDA, palmitic acid, and 2-ClHDA-dma, were
analyzed for their cytotoxic potential in addition to 2-ClHDA.
Cytotoxicity decreased in the order 2-ClHDA4HDA4palmitic
acid42-ClHDA-dma (Fig. 4B). In these experiments 2-ClHDA
reduced metabolic activity by 60 (25 mM) and 90% (50 mM),
whereas the nonchlorinated analogue HDA impaired metabolic
activity by approximately 40 (25 mM) and 50% (50 mM). Palmitic
acid, a fatty acid with potent lipotoxic properties, induced a 20%
decrease in MTT reduction at the highest concentration used
(50 mM). The chemically inert 2-ClHDA-dma was without effect.or presence of (A) 2-ClHDA or (B) reagent HOCl at the indicated concentrations for the
sed as % of controls and represent mean values7SD of triplicate (A) or quadruplicate
rent C16 compounds used in MTT assays. (B) Cells were challenged overnight with
ed by the MTT test. Results are expressed as % of controls and represent mean
p o 0.001, two-way ANOVA).
A. U¨llen et al. / Free Radical Biology and Medicine 53 (2012) 1770–17811776Hence, the presence of a chlorine atom signiﬁcantly potentiates the
cytotoxic properties of HDA, indicating that 2-ClHDA is a mediator
with high lipotoxic potential.
2-ClHDA impairs mitochondrial function and induces apoptosis
in BMVEC
To determine whether impaired MTT reduction is accompa-
nied by mitochondrial dysfunction Dcm was analyzed using JC-1
as a ﬂuorophore. DMSO used as vehicle was without effect onFig. 5. 2-ClHDA induces mitochondrial dysfunction, increases DCFDA ﬂuorescence, and
(A) 2-ClHDA or (B) reagent HOCl at the indicated concentrations for the indicated tim
calculated by division of red by green ﬂuorescence. Results are expressed as % of red t
three independent experiments. (C) The cellular redox status was determined using
nonﬂuorescent carboxy-H2DCFDA followed by treatment with 2-ClHDA at the indica
expressed as % of control and represents the mean 7 SD of three independent experim
(v/v). (D) Cells were incubated with 2-ClHDA (5 h) before caspase 3 measurement.
apoptosis. Procaspase 3 processing was analyzed using rabbit polyclonal anti-caspase
visualized using horseradish peroxidase-conjugated secondary antibody and the EC
determined as outlined under Materials and methods. Results represent means7SD from
Student’s t test). (E) Cells were incubated with 2-ClHDA (5 h) and intracellular ATP c
represent means7SD of four independent experiments (nnnpo0.01, one way ANOVA)Dcm (Supplementary Fig. IB). Results of these measurements
(Figs. 5A and B) revealed that both 2-ClHDA and HOCl impaired
Dcm, but with different efﬁcacies: whereas the IC50 values for
2-ClHDA were E25, 13, and 5 mM at 1, 3, and 5 h, the correspond-
ing values for reagent HOCl were 500 (3 h) and 350 mM (5 h). Thus
after a 5-h incubation 2-ClHDA was 70-fold more efﬁcient in
promoting mitochondrial alterations than reagent HOCl.
To establish if 2-ClHDA-mediated mitochondrial dysfunction
leads to alterations of intracellular redox balance the redox-
sensitive dye carboxy-H2DCFDA was used. Whereas the vehicleleads to apoptosis in BMVEC. Cells were incubated in the absence or presence of
e periods. After treatment, Dcm was analyzed using the JC-1 assay. Data were
o green ﬂuorescence ratio compared to controls and represent the means7SD of
the redox-sensitive compound carboxy-H2DCFDA. Cells were preincubated with
ted concentrations for the indicated time periods. The ﬂuorescence intensity is
ents (nnnp o 0.001; two-way ANOVA). Control, no addition; vehicle, 0.4% DMSO
Staurosporine (stauro.) and colchicine (colch.) were used as known inducers of
3 as primary antibody (top). Procaspase 3 (32 kDa) and caspase 3 (17 kDa) were
L system (C, control; veh, vehicle control, DMSO 0.4%). Caspase 3 activity was
triplicate determinations (npo0.05, nnnpo0.001, two-way ANOVA; ###po0.001,
oncentrations were analyzed as described under Materials and methods. Results
.
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15 and 50 mM (Fig. 5C), concentrations that also decreased MTT
reduction and mitochondrial function of BMVEC (Fig. 5A).
2-ClHDA caused an increase in DCF-dependent ﬂuorescence that
is suggestive of increased ROS production. 2-ClHDA-induced
DCFDA conversion was blocked by the thiol-containing antiox-
idant NAC (Supplementary Fig. II). To investigate whether
2-ClHDA induces apoptosis procaspase 3 activation was analyzed.
The known inducers of apoptosis staurosporine and colchicine
served as controls. 2-ClHDA concentrations Z5 mM induced
procaspase 3 processing (Fig. 5D, top). Concentrations of
5–10 mM induced partial proteolytic cleavage of procaspase 3,
and a concentration of 25 mM 2-ClHDA resulted in almost quanti-
tative conversion of procaspase 3 into active caspase 3. This was
also reﬂected by caspase 3 activity measurements (Fig. 5D, bot-
tom): 2-ClHDA at 10 and 25 mM induced caspase 3 activity
approximately two- and threefold over vehicle controls. 2-ClHDA-
and staurosporine-induced caspase 3 activation was eliminated in
the presence of the inhibitor Ac-DEVD-CHO. Mitochondrial func-
tion was assessed by measuring cellular ATP concentrations. These
analyses revealed that 2-ClHDA severely depleted (70–90%) the
cellular ATP pool in comparison to vehicle-treated cells (Fig. 5E).
Screening for cytoprotective polyphenols
Increasing evidence suggests that somemembers of the ﬂavonoid
and nonﬂavonoid polyphenol family display neuroprotective proper-
ties [31,32]. We therefore investigated the effects of representative
polyphenols (Supplementary Fig. III) on MTT reduction. Under the
experimental conditions applied, apigenin (a ﬂavone), curcumin (a
diarylheptanoid), and resveratrol (a stilbenoid) decreased metabolic
activity, indicative of mitochondrial dysfunction (Supplementary
Fig. IV). The remaining compounds, i.e., genistein (an isoﬂavone),
naringenin (a ﬂavanone), and phloretin (a dihydrochalcone), had
either no (except genistein at 100 mM) or beneﬁcial effects. To
provide a more direct measure of mitochondrial function we
analyzed cellular ATP levels in polyphenol-supplemented BMVEC
(Supplementary Fig. V). The most deleterious effects were observed
in curcumin-treated cells in which intracellular ATP was almost
completely depleted. Apigenin, genistein (at low concentrations),
naringenin, and resveratrol were without signiﬁcant effects, whereas
phloretin (and genistein at 100 mM) signiﬁcantly increased the
cellular ATP content (Supplementary Fig. V).
Next, the potential of genistein, naringenin, and phloretin to
ameliorate 2-ClHDA-induced cytotoxicity was investigated in more
detail. Under the experimental conditions applied genistein (up to
100 mM) had no signiﬁcant effect on BMVEC survival in the presence
of 2-ClHDA (Fig. 6A). Naringenin slightly but signiﬁcantly increased
MTT reduction, whereas phloretin provided the most pronounced
protection against 2-ClHDA-induced metabolic dysfunction. Most
importantly, phloretin provided protection also at 25 and 50 mM
(Fig. 6B).
To get an insight into the structural requirements for cell
protection, the efﬁcacy of phloretin was compared with that of
its naturally occurring glycosylated dietary precursor phloridzin
(for structure see Supplementary Fig. III). In contrast to nonglyco-
sylated phloretin, its glycosylated analogue was without effect or
even decreased the metabolic activity of BMVEC (Fig. 6C). These
data suggest that the hydroxyl group at C2 of phloretin is probably
involved in BMVEC protection against 2-ClHDA cytotoxicity.
Finally we investigated the effects of phloretin on caspase
3 activation and the cellular ATP status in 2-ClHDA-treated
cells. Basal caspase 3 activity was unaffected by phloretin alone.
However, activity signiﬁcantly increased in response to 15 mM
2-ClHDA and was reduced to control levels when cells were
incubated in the presence of 2-ClHDA and phloretin (Fig. 6D).A similar rescue phenotype was observed for cellular ATP levels:
2-ClHDA reduced cellular ATP concentrations by approximately
80% in comparison to vehicle-treated cells. However, the presence
of phloretin had a pronounced protective function and partially
preserved the intracellular ATP content (Fig. 6E).
Phloretin restores barrier function of 2-ClHDA-treated BMVEC
To determine the effects of phloretin on 2-ClHDA-mediated
barrier dysfunction BMVEC were pretreated with phloretin before
challenge with 2-ClHDA and impedance was monitored using the
ECIS system. Measuring barrier function (4 kHz) and the integrity
of the cell monolayer (64 kHz) revealed that barrier dysfunction
was rapidly induced in response to 2-ClHDA (Fig. 7A; the 30-h
time point is shown in Fig. 7B). Disruption of the cell monolayer
lagged by approximately 2–2.5 h behind (Fig. 7C; 30-h time point
is shown in Fig. 7D). 2-ClHDA-induced barrier dysfunction was
attenuated by phloretin (Fig. 7A), whereas the integrity of the cell
monolayer was almost completely conserved in the presence of
phloretin (Fig. 7C).
Phloretin reduces cellular 2-ClHDA content
Phloretin is a nonspeciﬁc inhibitor of cellular fatty acid uptake
[33]; we have investigated whether it would also interfere with
chlorinated fatty aldehyde uptake. Phloretin pretreatment signif-
icantly decreased the amount of cell-associated 2-ClHDA at all
time points investigated (Fig. 8A); these data suggest inhibition of
2-ClHDA uptake by phloretin. Surprisingly, NICI–GC–MS data also
revealed that 2-ClHDA levels in the cellular supernatant supple-
mented with phloretin were signiﬁcantly lower compared to
controls; again, this effect was time-dependent (Fig. 8B). Whether
these observations are due to covalent adduct formation between
2-ClHDA and phloretin is currently under investigation.Discussion
The ﬁndings of this in vitro study strengthen the concept that
reactive aldehydes generated under (neuro)inﬂammatory condi-
tions can induce BBB dysfunction [34]. Our data demonstrate that
2-ClHDA (a fatty aldehyde generated via MPO-speciﬁc pathways)
impairs metabolic activity, induces mitochondrial dysfunction,
and leads to increased DCF-dependent ﬂuorescence being indica-
tive of ROS generation in primary BMVEC. In addition, 2-ClHDA
potently induces apoptosis at concentrations that are present in
human atherosclerotic lesion material [21] and in brains of mice
with endotoxin-induced neuroinﬂammation [17]. Our ﬁnding that
phloretin alleviates 2-ClHDA-induced barrier dysfunction could
have therapeutic potential in a setting in which BBB function is
compromised under conditions of oxidative/chlorinative stress.
Results of this study demonstrate that BMVEC actively meta-
bolize 2-ClHDA to 2-ClHOH and 2-ClHA. This pathway was shown
to depend on fatty aldehyde dehydrogenase (ALDH3A2) activity
[25] in coronary artery endothelial cells [30]. ALDH3A2 deﬁciency
results in ichthyosis, spastic paraplegia, and mental retardation
probably due to abnormal membrane lipid accumulation in skin
and brain and formation of Schiff’s base adducts with lipids and/or
proteins [35]. The precursor–product analyses performed during
this study revealed that only 25% of initially added chlorinated
fatty aldehyde was recovered as 2-ClHDA, 2-ClHOH, or 2-ClHA.
There are several plausible explanations for this loss: (i) 2-ClHA is
incorporated into the complex lipid fraction (Fig. 2D), (ii) 2-ClHDA
is able to form Schiff’s base adducts with ethanolamine-containing
glycerophospholipids and/or the e-amino group of protein lysine
Fig. 6. Impact of selected polyphenols on 2-ClHDA-induced cell death in BMVEC. Cells were preincubated in the presence of the indicated concentrations of genistein,
naringenin, phloretin, or phloridzin. After an incubation in the presence of 2-ClHDA MTT tests were performed after (A) 16 or (B, C) 5 h. Results are expressed as % of
controls and represent mean values7SD of quadruplicate determinations (nnpo0.01, nnnpo0.001, one-way ANOVA). (D) Basal and 2-ClHDA-induced (5 h) caspase
3 activity was measured in the absence or presence of the indicated phloretin concentrations. DMSO (0.4%) was used as vehicle control. Results are expressed as % of
controls and represent mean values7SD of triplicate determinations (nnpo0.01, one way ANOVA; #po0.05, Student’s t test). (E) After an incubation with vehicle (DMSO,
0.4%) or 2-ClHDA in the absence or presence of indicated phloretin concentrations cellular ATP concentrations were quantitated. Results represent mean values7SD of
triplicate determinations (nnnpo0.001, one-way ANOVA; ##po0.05, Student’s t test).
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b-oxidation starting at the o-carboxylic acid function [38].
Of note, the o-oxidation pathway is also active in brain [39],
although it is not clear whether brain-derived metabolites accu-
mulate in cerebrospinal ﬂuid or the peripheral circulation.
o-Oxidation of chlorinated fatty aldehydes may also be active in
the cerebrovasculature: this is supported by data demonstratingthat BMVEC are able to oxidize 20-hydroxyeicosatetraenoic acid
to 20-carboxyeicosatetraenoic acid and chain-shortened b-oxida-
tion-derived dicarboxylic acid metabolites [40].
With regard to the MTT results, 2-ClHDA displayed higher
cytotoxicity toward BMVEC compared to reagent HOCl and structu-
rally related C16 analogues (Figs. 3 and 4). Because of relatively low
target selectivity it might be reasonable to assume that a major
Fig. 8. Phloretin reduces intra- and extracellular 2-ClHDA levels in BMVEC cultures. After pretreatment with phloretin (100 mM, 1 h) cells (9105) were incubated with
25 mM 2-CHDA. At the indicated times cellular lipids and lipids of the cellular supernatant were extracted. After conversion to PFB-oxime derivatives 2-ClHDA
concentrations in (A) cellular and (B) medium lipid extracts were quantitated by NICI–GC–MS analysis. Results are expressed as % of added 2-ClHDA and represent mean
values7SD of triplicate determinations (nnnpo0.001, two-way ANOVA).
Fig. 7. Phloretin rescues barrier function of 2-ClHDA-treated BMVEC. Cells were plated on gold microelectrodes and cultured to conﬂuence. Impedance of hydrocortisone-
induced monolayers (7.5104 cells) was continuously monitored at (A) 4 kHz and (C) 64 kHz. The corresponding 30-h time points are shown in (B) and (D). After
stabilization, cells were pretreated with 100 mM phloretin or vehicle for 3 h and then challenged with 25 mM 2-ClHDA. Impedance values were normalized to treatment
start and represent mean values7SD of four independent experiments (nnpo0.01, nnnpo0.001, Student’s t test).
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at the extrafacial leaﬂet of the plasma membrane. The cytotoxic
properties of C16 analogues decreased in the order 2-ClHDA4
HDA4palmitic acid42-ClHDA-dma (Fig. 4). In a manner similar to
that observed here, 2-iodohexadeacanal (the major iodolipid in
thyroid gland [41]) but not hexadecanal inhibited cell proliferationin a rat model of goiter [42]. Chlorinated lipids are potent signaling
mediators: 2-ClHDA activates COX-2 [43] and is an inhibitor of eNOS
biosynthesis [18]. Interestingly, a structural analogue of 2-ClHDA,
2-bromopalmitate, is a potent inhibitor of protein acylation, a key
event targeting eNOS to the Golgi complex and cholesterol-rich
microdomains of the plasma membranes [44].
A. U¨llen et al. / Free Radical Biology and Medicine 53 (2012) 1770–17811780Emerging evidence suggests that mitochondrial dysfunction
plays a major role in neurological disorders such as Alzheimer
disease, multiple sclerosis, Parkinson disease, and stroke [45]. It is
well established that electrophilic lipids, such as 4-hydroxy-2-
nonenal, the cyclopentenone 15-deoxy-D12,14-prostaglandin J2,
and 15-J2-isoprostane, induce ROS formation in endothelial cells,
most probably because of direct interaction with mitochondria
and/or alterations of the intracellular redox balance [46]. These
pathophysiological conditions might have particularly deleterious
consequences on transport systems at the BBB. BMVEC have a
high density of mitochondria, which reﬂects the energy demand
necessary to fuel the elaborately developed (ATP-dependent)
transport systems present at either the luminal or the abluminal
side of the BBB [1]. During normal oxidative phosphorylation
electrons leak out of the electron transport chain, giving rise to
the formation of superoxide anions, an event that might be
prevalent at the BBB. Superoxide anions are generated at both,
complex I (NADH dehydrogenase) and complex III (ubiquinone Q-
cytochrome b) and alterations in the redox status of these enzyme
complexes result in excessive production of ROS [47]. Subsequent
dismutation of superoxide anion radical to H2O2 could further
fuel the MPO–H2O2–chloride system.
Endothelial barrier modulation by reactive aldehydes includes
Michael adduct formation, increased protein tyrosine phosphoryla-
tion, redox-dependent mechanisms due to thiol depletion and/or
mitochondrial dysfunction, reorganization of the endothelial cytos-
keleton, and integrin-based events [48] or activation of matrix
metalloproteinases [49]. In human BMVEC cultures it was demon-
strated that Cyp2E1-dependent oxidation of ethanol to acetic
aldehyde results in ROS production, subsequent activation of
myosin light-chain kinase, phosphorylation of tight-junction pro-
teins, increased endothelial permeability, and enhanced monocyte
migration across the BBB [50]. In a guinea pig model of neurotoxi-
city increased 4-hydroxy-2-nonenal formation was accompanied
by altered distribution of the tight-junction-associated proteins
zonula occludens-1 and claudin-5 [51].
One of the major ﬁndings obtained here is a potent rescue
capacity of the dihydrochalcone-type polyphenol phloretin.
Phloretin is a nonspeciﬁc fatty acid uptake inhibitor at the BBB
[52]. Our data suggest that phloretin could also interfere with
2-ClHDA uptake by BMVEC, thereby attenuating adverse effects.
Among the various polyphenols investigated, phloretin effectively
suppressed cytotoxicity and barrier dysfunction (Figs. 6 and 7),
observations in line with our preliminary hypothesis that
phloretin inhibits cellular 2-ClHDA-mediated uptake. However,
2-ClHDA concentrations in the cellular supernatant were also
signiﬁcantly lower compared to incubations in the absence of
phloretin. This observation raises the possibility that phloretin
could form covalent adducts with the chlorinated aldehyde.
Phloridzin, the glucoside of phloretin, was without beneﬁcial
effects on BMVEC, suggesting that 2-ClHDA trapping is speciﬁc
to phloretin. The underlying mechanisms are currently unclear
and under investigation by our group.
In conclusion, the results of this study demonstrate that
2-ClHDA has deleterious effects on BMVEC function, indicating
that activation of neutrophils and subsequent release of 2-ClHDA
could contribute to BBB dysfunction under pathological condi-
tions. Findings that phloretin potently ameliorates these adverse
effects opens potentially new pharmacotherapeutical strategies to
interfere with aldehyde-mediated BBB dysfunction.Acknowledgments
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